James D Brenton

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/5142681/james-d-brenton-publications-by-year.pdf
Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

169 papers	19,630 citations	57 h-index	139 g-index
200 ext. papers	23,777 ext. citations	11.5 avg, IF	6.13 L-index

#	Paper	IF	Citations
169	Refined characterization of circulating tumor DNA through biological feature integration.. *Scientific Reports*, **2022**, 12, 1928	4.9	2
168	Immunohistochemistry and Next-generation Sequencing Are Complementary Tests in Identifying PTEN Abnormality in Endometrial Carcinoma Biopsies. *International Journal of Gynecological Pathology*, **2022**, 41, 12-19	3.2	3
167	The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma.. *Clinical Cancer Research*, **2022**, OF1-OF12	12.9	1
166	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. *Cancer Epidemiology Biomarkers and Prevention*, **2021**, 30, 217-228	4	7
165	Validated biomarker assays confirm ARID1A loss is confounded with MMR deficiency, CD8 TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas.. *Journal of Pathology*, **2021**,	9.4	3
164	DNA Methylation Profiles of Ovarian Clear Cell Carcinoma. *Cancer Epidemiology Biomarkers and Prevention*, **2021**,	4	2
163	Promises and challenges of adoptive T-cell therapies for solid tumours. *British Journal of Cancer*, **2021**, 124, 1759-1776	8.7	19
162	Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2. *Gynecologic Oncology*, **2021**, 161, 668-675	4.9	0
161	Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses. *Modern Pathology*, **2021**, 34, 194-206	9.8	6
160	Ultrasound-guided targeted biopsies of CT-based radiomic tumour habitats: technical development and initial experience in metastatic ovarian cancer. *European Radiology*, **2021**, 31, 3765-3772	8	6
159	Biomarkers for site-specific response to neoadjuvant chemotherapy in epithelial ovarian cancer: relating MRI changes to tumour cell load and necrosis. *British Journal of Cancer*, **2021**, 124, 1130-1137	8.7	2
158	FrenchFISH: Poisson Models for Quantifying DNA Copy Number From Fluorescence In Situ Hybridization of Tissue Sections. *JCO Clinical Cancer Informatics*, **2021**, 5, 176-186	5.2	1
157	Can integrative biomarker approaches improve prediction of platinum and PARP inhibitor response in ovarian cancer?. *Seminars in Cancer Biology*, **2021**, 77, 67-82	12.7	5
156	TGFBI Production by Macrophages Contributes to an Immunosuppressive Microenvironment in Ovarian Cancer. *Cancer Research*, **2021**, 81, 5706-5719	10.1	9
155	Genomic landscape of platinum resistant and sensitive testicular cancers. *Nature Communications*, **2020**, 11, 2189	17.4	23
154	Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy. *Nature Genetics*, **2020**, 52, 582-593	36.3	64
153	Proteomic analysis of transitional cell carcinoma-like variant of tubo-ovarian high-grade serous carcinoma. *Human Pathology*, **2020**, 101, 40-52	3.7	2

152	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). *Clinical Cancer Research*, **2020**, 26, 5411-5423	12.9	21
151	Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium. *British Journal of Cancer*, **2020**, 123, 793-802	8.7	16
150	Kinome capture sequencing of high-grade serous ovarian carcinoma reveals novel mutations in the JAK3 gene. *PLoS ONE*, **2020**, 15, e0235766	3.7	1
149	Is an Actionable Mutation in High Grade Serous Ovarian Carcinoma. *Cells*, **2020**, 9,	7.9	3
148	Combining measures of immune infiltration shows additive effect on survival prediction in high-grade serous ovarian carcinoma. *British Journal of Cancer*, **2020**, 122, 1803-1810	8.7	11
147	Detection of ctDNA from Dried Blood Spots after DNA Size Selection. *Clinical Chemistry*, **2020**, 66, 697-705	9.5	16
146	Integrative radiogenomics for virtual biopsy and treatment monitoring in ovarian cancer. *Insights Into Imaging*, **2020**, 11, 94	5.6	16
145	p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies. *Journal of Pathology*, **2020**, 250, 336-345	9.4	56
144	Integrated Multi-Tumor Radio-Genomic Marker of Outcomes in Patients with High Serous Ovarian Carcinoma. *Cancers*, **2020**, 12,	6.6	7
143	Tissue-specific and interpretable sub-segmentation of whole tumour burden on CT images by unsupervised fuzzy clustering. *Computers in Biology and Medicine*, **2020**, 120, 103751	7	14
142	Diffusion-weighted MRI in Advanced Epithelial Ovarian Cancer: Apparent Diffusion Coefficient as a Response Marker. *Radiology*, **2019**, 293, 374-383	20.5	11
141	Shared heritability and functional enrichment across six solid cancers. *Nature Communications*, **2019**, 10, 431	17.4	45
140	Sodium MRI with 3D-cones as a measure of tumour cellularity in high grade serous ovarian cancer. *European Journal of Radiology Open*, **2019**, 6, 156-162	2.6	7
139	A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. *Modern Pathology*, **2019**, 32, 1834-1846	9.8	21
138	Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women. *Cancer Medicine*, **2019**, 8, 2503-2513	4.8	4
137	Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. *Cancer*, **2019**, 125, 1963-1972	6.4	22
136	Diffusion kurtosis MRI as a predictive biomarker of response to neoadjuvant chemotherapy in high grade serous ovarian cancer. *Scientific Reports*, **2019**, 9, 10742	4.9	6
135	A randomized double-blind placebo-controlled phase II trial comparing gemcitabine monotherapy to gemcitabine in combination with adavosertib in women with recurrent, platinum resistant epithelial ovarian cancer: A trial of the Princess Margaret, California, Chicago and Mayo Phase II Consortia.. *Journal of Clinical Oncology*, **2019**, 37, 5518-5518	2.2	11

134	Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. *Lancet, The*, **2019**, 394, 2084-2095	40	88
133	Genomic Applications in Ovarian Cancer **2019**, 471-482		
132	Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. *Cancer Discovery*, **2019**, 9, 210-219	24.4	142
131	Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. *Cancer Research*, **2019**, 79, 505-517	10.1	28
130	MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. *Mayo Clinic Proceedings*, **2018**, 93, 307-320	6.4	14
129	Personalising Treatment for High-Grade Serous Ovarian Carcinoma. *Clinical Oncology*, **2018**, 30, 515-524	2.8	10
128	Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. *Journal of Pathology: Clinical Research*, **2018**, 4, 250-261	5.3	38
127	You won□t believe this old test □that does cheap single-cell mutation detection. *Journal of Pathology: Clinical Research*, **2018**, 4, 149-153	5.3	5
126	Copy number signatures and mutational processes in ovarian carcinoma. *Nature Genetics*, **2018**, 50, 1262-1270	36.3	155
125	Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers. *Cancer Discovery*, **2018**, 8, 304-319	24.4	157
124	Enhanced detection of circulating tumor DNA by fragment size analysis. *Science Translational Medicine*, **2018**, 10,	17.5	350
123	Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine Programme. *ESMO Open*, **2018**, 3, e000408	6	2
122	Effects of Collection and Processing Procedures on Plasma Circulating Cell-Free DNA from Cancer Patients. *Journal of Molecular Diagnostics*, **2018**, 20, 883-892	5.1	57
121	Liquid biopsies come of age: towards implementation of circulating tumour DNA. *Nature Reviews Cancer*, **2017**, 17, 223-238	31.3	1192
120	CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours. *Nature Communications*, **2017**, 8, 14432	17.4	251
119	Development of Cell-Permeable, Non-Helical Constrained Peptides to Target a Key Protein□Protein Interaction in Ovarian Cancer. *Angewandte Chemie*, **2017**, 129, 539-544	3.6	6
118	Development of Cell-Permeable, Non-Helical Constrained Peptides to Target a Key Protein-Protein Interaction in Ovarian Cancer. *Angewandte Chemie - International Edition*, **2017**, 56, 524-529	16.4	35
117	Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. *Lancet Oncology, The*, **2017**, 18, 75-87	21.7	706

116	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. *Nature Genetics*, **2017**, 49, 680-691	36.3	190
115	Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. *JAMA Oncology*, **2017**, 3, e173290	13.4	152
114	Association between tumour infiltrating lymphocytes, histotype and clinical outcome in epithelial ovarian cancer. *BMC Cancer*, **2017**, 17, 657	4.8	29
113	Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2. *Gynecologic Oncology*, **2017**, 147, 267-275	4.9	163
112	Phase II open-label randomized multi-centre study of neoadjuvant olaparib in patients (pts) with platinum sensitive (PS) relapsed high grade serous ovarian cancer (OC): The NEO trial.. *Journal of Clinical Oncology*, **2017**, 35, TPS5608-TPS5608	2.2	2
111	Germline whole exome sequencing and large-scale replication identifies as a likely high grade serous ovarian cancer susceptibility gene. *Oncotarget*, **2017**, 8, 50930-50940	3.3	30
110	Sequencing Structural Variants in Cancer for Precision Therapeutics. *Trends in Genetics*, **2016**, 32, 530-548	8.5	55
109	Optimized p53 immunohistochemistry is an accurate predictor of mutation in ovarian carcinoma. *Journal of Pathology: Clinical Research*, **2016**, 2, 247-258	5.3	192
108	New paradigms for BRCA1/BRCA2 testing in women with ovarian cancer: results of the Genetic Testing in Epithelial Ovarian Cancer (GTEOC) study. *Journal of Medical Genetics*, **2016**, 53, 655-61	5.8	47
107	Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer. *Breast Cancer Research*, **2016**, 18, 21	8.3	43
106	Models of endometriosis and their utility in studying progression to ovarian clear cell carcinoma. *Journal of Pathology*, **2016**, 238, 185-96	9.4	29
105	Refinement of prespecified cutoff for genomic loss of heterozygosity (LOH) in ARIEL2 part 1: A phase II study of rucaparib in patients (pts) with high grade ovarian carcinoma (HGOC).. *Journal of Clinical Oncology*, **2016**, 34, 5540-5540	2.2	16
104	Feasibility of monitoring response to the PARP inhibitor rucaparib with targeted deep sequencing of circulating tumor DNA (ctDNA) in women with high-grade serous carcinoma on the ARIEL2 trial.. *Journal of Clinical Oncology*, **2016**, 34, 5549-5549	2.2	8
103	PISARRO: A EUTROC phase Ib study of APR-246 in combination with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in platinum sensitive relapsed high grade serous ovarian cancer (HGSOC).. *Journal of Clinical Oncology*, **2016**, 34, 5571-5571	2.2	12
102	Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study. *PLoS Medicine*, **2016**, 13, e1002198	11.6	151
101	CALIBRATE: Intensive profiling of circulating tumour DNA (ctDNA) from patients participating in experimental therapeutics trials including mutational profiles and copy number changes.. *Journal of Clinical Oncology*, **2016**, 34, 11530-11530	2.2	
100	Circulating tumour DNA carrying patient-specific mutations in TP53 as an early response biomarker in relapsed high grade serous ovarian cancer.. *Journal of Clinical Oncology*, **2016**, 34, e23040-e23040	2.2	1
99	SPARC Regulates Transforming Growth Factor Beta Induced (TGFBI) Extracellular Matrix Deposition and Paclitaxel Response in Ovarian Cancer Cells. *PLoS ONE*, **2016**, 11, e0162698	3.7	20

98	Intensive cisplatin/oral etoposide for epithelial ovarian cancer: the Cambridge Gynae-Oncology Centre experience: too toxic for relapse?. *Anti-Cancer Drugs*, **2016**, 27, 239-44	2.4	0
97	Identification and Development of 2,3-Dihydropyrrolo[1,2-a]quinazolin-5(1H)-one Inhibitors Targeting Bromodomains within the Switch/Sucrose Nonfermenting Complex. *Journal of Medicinal Chemistry*, **2016**, 59, 5095-101	8.3	35
96	Structural and calorimetric studies demonstrate that the hepatocyte nuclear factor 1 (HNF1) transcription factor is imported into the nucleus via a monopartite NLS sequence. *Journal of Structural Biology*, **2016**, 195, 273-281	3.4	4
95	A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer. *Molecular Oncology*, **2015**, 9, 115-27	7.9	35
94	Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis. *PLoS Medicine*, **2015**, 12, e1001789	11.6	230
93	Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control. *Molecular Oncology*, **2015**, 9, 791-805	7.9	24
92	Molecular pathogenesis of ovarian clear cell carcinoma. *Future Oncology*, **2015**, 11, 1389-405	3.6	17
91	Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. *Nature Reviews Cancer*, **2015**, 15, 668-79	31.3	581
90	A Bayesian adaptive design for biomarker trials with linked treatments. *British Journal of Cancer*, **2015**, 113, 699-705	8.7	20
89	Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer. *Clinical Cancer Research*, **2015**, 21, 652-7	12.9	107
88	Genomic Applications in Epithelial Ovarian Malignancies **2015**, 489-502		
87	Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes. *PLoS ONE*, **2014**, 9, e103988	3.7	228
86	Combined image and genomic analysis of high-grade serous ovarian cancer reveals PTEN loss as a common driver event and prognostic classifier. *Genome Biology*, **2014**, 15, 526	18.3	74
85	Phylogenetic quantification of intra-tumour heterogeneity. *PLoS Computational Biology*, **2014**, 10, e1003535		91
84	Boosting Wnt activity during colorectal cancer progression through selective hypermethylation of Wnt signaling antagonists. *BMC Cancer*, **2014**, 14, 891	4.8	55
83	Repeatability of quantitative FDG-PET/CT and contrast-enhanced CT in recurrent ovarian carcinoma: test-retest measurements for tumor FDG uptake, diameter, and volume. *Clinical Cancer Research*, **2014**, 20, 2751-60	12.9	36
82	Conditions associated with circulating tumor-associated folate receptor 1 protein in healthy men and women. *PLoS ONE*, **2014**, 9, e96542	3.7	9
81	A metadata-aware application for remote scoring and exchange of tissue microarray images. *BMC Bioinformatics*, **2013**, 14, 147	3.6	1

80	Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. *Lancet Oncology, The*, **2013**, 14, 853-62	21.7	248
79	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. *Nature Genetics*, **2013**, 45, 362-70, 370e1-2	36.3	267
78	Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. *Nature*, **2013**, 497, 108-12	50.4	1220
77	The Xenopus Tgfbi is required for embryogenesis through regulation of canonical Wnt signalling. *Developmental Biology*, **2013**, 379, 16-27	3.1	5
76	Increased endothelial cell selectivity of triazole-bridged dihalogenated A-ring analogues of combretastatin A-1. *Bioorganic and Medicinal Chemistry*, **2012**, 20, 1749-59	3.4	17
75	A-ring dihalogenation increases the cellular activity of combretastatin-templated tetrazoles. *ACS Medicinal Chemistry Letters*, **2012**, 3, 177-81	4.3	36
74	Complex stiffness gradient substrates for studying mechanotactic cell migration. *Advanced Materials*, **2012**, 24, 6059-64	24	91
73	Structural analysis of the genome of breast cancer cell line ZR-75-30 identifies twelve expressed fusion genes. *BMC Genomics*, **2012**, 13, 719	4.5	28
72	β integrin modulates transforming growth factor beta induced (TGFBI) function and paclitaxel response in ovarian cancer cells. *Molecular Cancer*, **2012**, 11, 36	42.1	42
71	The role of tandem duplicator phenotype in tumour evolution in high-grade serous ovarian cancer. *Journal of Pathology*, **2012**, 226, 703-12	9.4	48
70	The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. *Nature*, **2012**, 486, 346-52	50.4	3479
69	Tandem duplication of chromosomal segments is common in ovarian and breast cancer genomes. *Journal of Pathology*, **2012**, 227, 446-55	9.4	72
68	Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. *Science Translational Medicine*, **2012**, 4, 136ra68	17.5	882
67	Advanced ovarian cancer: multiparametric MR imaging demonstrates response- and metastasis-specific effects. *Radiology*, **2012**, 263, 149-59	20.5	77
66	Evolution of platinum resistance in high-grade serous ovarian cancer. *Lancet Oncology, The*, **2011**, 12, 1169-74	21.7	141
65	Rethinking ovarian cancer: recommendations for improving outcomes. *Nature Reviews Cancer*, **2011**, 11, 719-25	31.3	893
64	Intra-tumour genetic heterogeneity and poor chemoradiotherapy response in cervical cancer. *British Journal of Cancer*, **2011**, 104, 361-8	8.7	58
63	Total syntheses of subereamollines A and B. *Organic and Biomolecular Chemistry*, **2011**, 9, 62-5	3.9	29

62	Ovarian clear cell carcinoma--bad endometriosis or bad endometrium?. *Journal of Pathology*, **2011**, 225, 157-60	9.4	21
61	Sequential DNA methylation changes are associated with DNMT3B overexpression in colorectal neoplastic progression. *Gut*, **2011**, 60, 499-508	19.2	116
60	Two novel determinants of etoposide resistance in small cell lung cancer. *Cancer Research*, **2011**, 71, 4877-87	10.1	28
59	New Insights into Tubulin Binders **2011**, 259-278		0
58	Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma. *Oncogene*, **2010**, 29, 4905-13	9.2	122
57	Bcl-2 and 1-integrin predict survival in a tissue microarray of small cell lung cancer. *British Journal of Cancer*, **2010**, 103, 1710-5	8.7	29
56	Slingshot: a PiggyBac based transposon system for tamoxifen-inducible Self-inactivatingP insertional mutagenesis. *Nucleic Acids Research*, **2010**, 38, e173	20.1	10
55	Tissue banking of diagnostic lung cancer biopsies for extraction of high quality RNA. *Journal of Thoracic Oncology*, **2010**, 5, 956-63	8.9	21
54	S94 Two novel determinants of etoposide resistance in small cell lung cancer. *Thorax*, **2010**, 65, A43-A44	7.3	
53	Evaluation of nonenhancing tumor fraction assessed by dynamic contrast-enhanced MRI subtraction as a predictor of decrease in tumor volume in response to chemoradiotherapy in advanced cervical cancer. *American Journal of Roentgenology*, **2010**, 195, 524-7	5.4	31
52	Antivascular and anticancer activity of dihalogenated A-ring analogues of combretastatin A-4. *MedChemComm*, **2010**, 1, 202	5	22
51	PathGrid: a service-orientated architecture for microscopy image analysis. *Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences*, **2010**, 368, 3937-52	3	4
50	Apparent diffusion coefficient and vascular signal fraction measurements with magnetic resonance imaging: feasibility in metastatic ovarian cancer at 3 Tesla: technical development. *European Radiology*, **2010**, 20, 491-6	8	53
49	Dynamic contrast-enhanced MRI in ovarian cancer: Initial experience at 3 tesla in primary and metastatic disease. *Magnetic Resonance in Medicine*, **2010**, 63, 1044-9	4.4	42
48	Total syntheses of the bromotyrosine-derived natural products ianthelline, 5-bromoverongamine and JBIR-44. *Tetrahedron Letters*, **2010**, 51, 4812-4814	2	15
47	Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. *Journal of Pathology*, **2010**, 221, 49-56	9.4	485
46	The specificity of the FOXL2 c.402C>G somatic mutation: a survey of solid tumors. *PLoS ONE*, **2009**, 4, e7988	3.7	71
45	One-stop diagnostic breast clinics: how often are breast cancers missed?. *British Journal of Cancer*, **2009**, 100, 1873-8	8.7	22

44	Chromosomal instability determines taxane response. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 8671-6	11.5	192
43	The pitfalls of platform comparison: DNA copy number array technologies assessed. *BMC Genomics*, **2009**, 10, 588	4.5	79
42	Metabolic characterization of primary and metastatic ovarian cancer by 1H-MRS in vivo at 3T. *Magnetic Resonance in Medicine*, **2009**, 62, 855-61	4.4	33
41	A metadata approach for clinical data management in translational genomics studies in breast cancer. *BMC Medical Genomics*, **2009**, 2, 66	3.7	18
40	Semiquantitative and quantitative dynamic contrast-enhanced magnetic resonance imaging measurements predict radiation response in cervix cancer. *International Journal of Radiation Oncology Biology Physics*, **2009**, 74, 766-73	4	127
39	Image-guided biopsy in patients with suspected ovarian carcinoma: a safe and effective technique?. *European Radiology*, **2009**, 19, 230-5	8	37
38	Mutation of FOXL2 in granulosa-cell tumors of the ovary. *New England Journal of Medicine*, **2009**, 360, 2719-29	59.2	551
37	Metadata-driven software for clinical trials **2009**,		8
36	Functional genomic analysis of drug sensitivity pathways to guide adjuvant strategies in breast cancer. *Breast Cancer Research*, **2008**, 10, 214	8.3	18
35	Somatically acquired hypomethylation of IGF2 in breast and colorectal cancer. *Human Molecular Genetics*, **2008**, 17, 2633-43	5.6	110
34	Genomic analysis of the 8p11-12 amplicon in familial breast cancer. *International Journal of Cancer*, **2007**, 120, 714-7	7.5	24
33	A gene-expression signature to predict survival in breast cancer across independent data sets. *Oncogene*, **2007**, 26, 1507-16	9.2	191
32	Using array-comparative genomic hybridization to define molecular portraits of primary breast cancers. *Oncogene*, **2007**, 26, 1959-70	9.2	88
31	High resolution melting for mutation scanning of TP53 exons 5-8. *BMC Cancer*, **2007**, 7, 168	4.8	108
30	Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. *Cancer Cell*, **2007**, 11, 498-512	24.3	305
29	The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel. *Cancer Cell*, **2007**, 12, 514-27	24.3	171
28	BEX2 is overexpressed in a subset of primary breast cancers and mediates nerve growth factor/nuclear factor-kappaB inhibition of apoptosis in breast cancer cell lines. *Cancer Research*, **2007**, 67, 6725-36	10.1	72
27	High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. *Genome Biology*, **2007**, 8, R215	18.3	230

26	Differential expression of selected histone modifier genes in human solid cancers. *BMC Genomics*, **2006**, 7, 90	4.5	186
25	Metabolic consequences of p300 gene deletion in human colon cancer cells. *Cancer Research*, **2006**, 66, 7606-14	10.1	26
24	Absence of p300 induces cellular phenotypic changes characteristic of epithelial to mesenchyme transition. *British Journal of Cancer*, **2006**, 94, 1326-32	8.7	36
23	A consensus prognostic gene expression classifier for ER positive breast cancer. *Genome Biology*, **2006**, 7, R101	18.3	75
22	MMASS: an optimized array-based method for assessing CpG island methylation. *Nucleic Acids Research*, **2006**, 34, e136	20.1	43
21	Molecular classification and molecular forecasting of breast cancer: ready for clinical application?. *Journal of Clinical Oncology*, **2005**, 23, 7350-60	2.2	696
20	Microarrays and breast cancer clinical studies: forgetting what we have not yet learnt. *Breast Cancer Research*, **2005**, 7, 96-9	8.3	22
19	Optimal amounts of fluorescent dye improve expression microarray results in tumor specimens. *Molecular Biotechnology*, **2005**, 30, 151-4	3	4
18	The External RNA Controls Consortium: a progress report. *Nature Methods*, **2005**, 2, 731-4	21.6	269
17	A 1 Mb minimal amplicon at 8p11-12 in breast cancer identifies new candidate oncogenes. *Oncogene*, **2005**, 24, 5235-45	9.2	130
16	Proposed methods for testing and selecting the ERCC external RNA controls. *BMC Genomics*, **2005**, 6, 150	4.5	104
15	A variational Bayesian mixture modelling framework for cluster analysis of gene-expression data. *Bioinformatics*, **2005**, 21, 3025-33	7.2	58
14	Microarray segmentation methods significantly influence data precision. *Nucleic Acids Research*, **2004**, 32, e50	20.1	45
13	Expression microarray reproducibility is improved by optimising purification steps in RNA amplification and labelling. *BMC Genomics*, **2004**, 5, 9	4.5	40
12	Predictive cancer genomics--what do we need?. *Lancet, The*, **2003**, 362, 340-1	40	14
11	Parallel analysis of sporadic primary ovarian carcinomas by spectral karyotyping, comparative genomic hybridization, and expression microarrays. *Cancer Research*, **2002**, 62, 3466-76	10.1	83
10	Molecular profiling of breast cancer: portraits but not physiognomy. *Breast Cancer Research*, **2001**, 3, 77-80	8.3	28
9	Imprinting and gene silencing in mice and Drosophila. *Novartis Foundation Symposium*, **1998**, 214, 233-44; discussion 244-50		1

List of Publications

8	An imprinting element from the mouse H19 locus functions as a silencer in Drosophila. *Nature Genetics*, **1997**, 16, 171-3	36.3	96
7	Detection of ctDNA from dried blood spots after DNA size selection		2
6	Polygenic Risk Modelling for Prediction of Epithelial Ovarian Cancer Risk		1
5	Selecting short DNA fragments in plasma improves detection of circulating tumour DNA		8
4	Copy-number signatures and mutational processes in ovarian carcinoma		3
3	Unraveling Tumor-Immune Heterogeneity in Advanced Ovarian Cancer Uncovers Immunogenic Effect of Chemotherapy		2
2	Computed Tomography Measures of Inter-site tumor Heterogeneity for Classifying Outcomes in High-Grade Serous Ovarian Carcinoma: a Retrospective Study		2
1	Prognostic and Immunological Significance of ARID1A Status in Endometriosis-Associated Ovarian Carcinoma		1